Literature DB >> 10950031

Long-term follow-up of Barrett's high-grade dysplasia.

A P Weston1, P Sharma, M Topalovski, R Richards, R Cherian, A Dixon.   

Abstract

OBJECTIVE: The management of Barrett's high-grade dysplasia (HGD) remains controversial. The aims of this study were to evaluate prospectively the outcome of unifocal HGD (uHGD) in patients with Barrett's esophagus, and to determine demographic and endoscopic features predictive of progression to multifocal HGD (mHGD) and/or adenocarcinoma.
METHODS: Consecutive Barrett's patients in whom uHGD was found at initial endoscopy or during surveillance underwent intensification of medical treatment and repeat endoscopy. The study endpoint was progression to mHGD or adenocarcinoma or HGD in conjunction with a dysplasia-associated lesion or mass (DALM). HGD diagnosis was confirmed by a second, blinded pathologist.
RESULTS: A total of 15 Barrett's patients with uHGD met inclusion criteria and have been prospectively followed for a mean +/- SD of 36.8 +/- 23.2 months. All were white and male, with a mean age +/- SD of 61.4 +/- 14.9 yr. Barrett's length varied from 1 to 13 cm (mean, +/- SD, 6.8 +/- 4 cm). Overall, eight (53.3%) uHGD progressed: four of 15 (26.7%) to frank cancer between 17 and 35 months of follow-up, two of 15 (13.3%) to mHGD with DALM in conjunction with one or more foci of possible intramucosal cancer after 12-91 months of follow-up, one of 15 (6.7%) to mHGD with a focus of possible intramucosal cancer after 14 months, and one of 15 (6.7%) to mHGD after 29 months. Seven of 15 (46.7%) uHGD have regressed, five to no dysplasia and two to LGD, over the course of follow-up ranging from 24 to 73 months (mean +/- SD, 43.3 +/- 19.9). All three patients with short-segment Barrett's esophagus with uHGD regressed. Fisher's exact test revealed that Barrett's length > or =3 cm and presence of hiatal hernia approached significance (p < 0.08) in predicting uHGD progression to mHGD/DALM/cancer. However, use of the log-rank test to account for differences in length of follow-up show no significance for hiatal hernia or Barrett's length.
CONCLUSIONS: Barrett's uHGD has a high risk for progressing to mHGD or cancer. Justification of an observational approach to uHGD should be discouraged. Markers of uHGD progression, as well as regression, are needed.

Entities:  

Mesh:

Year:  2000        PMID: 10950031     DOI: 10.1111/j.1572-0241.2000.02234.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  61 in total

1.  Observer variation in the diagnosis of superficial oesophageal adenocarcinoma: another spanner in the works?

Authors:  D Alderson
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

2.  Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer.

Authors:  H Barr
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 3.  Barrett's esophagus with high-grade dysplasia: focus on current treatment options.

Authors:  Leonidas Lekakos; Nikolaos P Karidis; Dimitrios Dimitroulis; Christos Tsigris; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

4.  Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?

Authors:  M S Dar; J R Goldblum; T W Rice; G W Falk
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 5.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

6.  Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.

Authors:  Chin Hur; Norman S Nishioka; G Scott Gazelle
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

7.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

Review 8.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

9.  Barrett's esophagus and the increasing role of endoluminal therapy.

Authors:  Michael S Smith; Charles J Lightdale
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

10.  Endoscopic resection techniques and ablative therapies for Barrett's neoplasia.

Authors:  Jacobo Ortiz-Fernández-Sordo; Adolfo Parra-Blanco; Alejandro García-Varona; María Rodríguez-Peláez; Erika Madrigal-Hoyos; Irving Waxman; Luis Rodrigo
Journal:  World J Gastrointest Endosc       Date:  2011-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.